Subjects that were assigned the probiotics and prednisolone treatment groups had delayed onset of SLE with a significant reduction in antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-ribonucleoprotein (anti-RNP), and severity of lipogranuloma lesions compared to positive controls (Mardani et al., 2019). The gene discussed is BTG3; the disease is systemic lupus erythematosus.